Genetic Technologies (AU:GTG)
ASX:GTG
Holding AU:GTG?
Track your performance easily

Genetic Technologies (GTG) Share Price & Analysis

4 Followers

GTG Stock Chart & Stats


Financials

Annual

GTG FAQ

What was Genetic Technologies’s price range in the past 12 months?
Genetic Technologies lowest share price was AU$0.04 and its highest was AU$0.19 in the past 12 months.
    What is Genetic Technologies’s market cap?
    Currently, no data Available
    When is Genetic Technologies’s upcoming earnings report date?
    Genetic Technologies’s upcoming earnings report date is Feb 26, 2025 which is in 113 days.
      How were Genetic Technologies’s earnings last quarter?
      Genetic Technologies released its earnings results on Aug 29, 2024. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.04.
        Is Genetic Technologies overvalued?
        According to Wall Street analysts Genetic Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Genetic Technologies pay dividends?
          Genetic Technologies does not currently pay dividends.
          What is Genetic Technologies’s EPS estimate?
          Genetic Technologies’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Genetic Technologies have?
          Genetic Technologies has 242,362,080 shares outstanding.
            What happened to Genetic Technologies’s price movement after its last earnings report?
            Genetic Technologies reported an EPS of -AU$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Genetic Technologies?
              Currently, no hedge funds are holding shares in AU:GTG
              ---

              Genetic Technologies Stock Smart Score

              Company Description

              Genetic Technologies

              Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Northwest Biotherapeutics
              Oncolytics Biotech
              CytoDyn
              BioNano Genomics
              Genetic Technologies
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis